dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Bidard, François-Clement |
dc.contributor.author | Kaklamani, Virginia |
dc.contributor.author | Neven, Patrick |
dc.contributor.author | Streich, Guillermo |
dc.contributor.author | Montero, Alberto J. |
dc.contributor.author | Forget, Frédéric |
dc.contributor.author | Cortés Castan, Javier |
dc.date.accessioned | 2022-11-04T08:45:50Z |
dc.date.available | 2022-11-04T08:45:50Z |
dc.date.issued | 2022-10-01 |
dc.identifier.citation | Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022 Oct 1;40(28):3246–56. |
dc.identifier.issn | 2045-2322 |
dc.identifier.uri | https://hdl.handle.net/11351/8393 |
dc.description | Elacestrant; Càncer de mama |
dc.language.iso | eng |
dc.publisher | American Society of Clinical Oncology |
dc.relation.ispartofseries | Journal of Clinical Oncology;40(28) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Tractament |
dc.subject | Medicaments antineoplàstics - Ús terapèutic |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Agents |
dc.subject.mesh | Treatment Outcome |
dc.title | Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1200/JCO.22.00338 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | antineoplásicos |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1200/JCO.22.00338 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Bidard FC] Institut Curie, Paris and Saint Cloud, France. Versailles Saint Quentin/Paris-Saclay University, Saint Cloud, France. [Kaklamani VG] University of Texas Health Sciences Center, San Antonio, TX. [Neven P] Universitaire Ziekenhuizen (UZ)—Leuven Cancer Institute, Leuven, Belgium. [Streich G] Centro Médico Austral, Buenos Aires, Argentina. [Montero AJ] University Hospitals Seidman Cancer Center-Case Western Reserve University, Cleveland, OH. [Forget F] Centre Hospitalier de l’Ardenne—Site de Libramont, Libramont-Chevigny, Belgium. [Cortés J] International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain. Scientific Department, Medica Scientia Innovation Research, Valencia, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain |
dc.identifier.pmid | 35584336 |
dc.identifier.wos | 000797636300010 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |